Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells

International Journal of Cancer

Volumn 114, Issue 2, 2005, Pages 195-201

  Hebert, Carla ^a   Siavash, Hessam ^a,b   Norris, Kathleen ^a   Nikitakis, Nikolaos G ^a,b   Sauk, John J ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Endostatin; Nitric oxide; Squamous carcinoma; VEGF, collagen XVIII

Indexed keywords

ADENOVEC; ADENOVIRUS VECTOR; AMINOGUANIDINE; COLLAGEN TYPE 18; DIPHENYLIODONIUM SALT; ENDOSTATIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; SCAVENGER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; GENE VECTOR; HUMAN; HUMAN CELL; HYPOXIA; MOUTH CARCINOMA; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN TYPE XVIII; DNA PRIMERS; ENDOSTATINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NITRIC OXIDE; NITRIC OXIDE DONORS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13244287812     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20692     Document Type: Article

References (33)

1. Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 1994;91:4229-33.
2. Oh SP, Warman ML, Seldin MF, Cheng SD, Knoll JH, Timmons S, Olsen BR Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 1994;19:494-9.
3. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 1998;16:319-28.
4. Rehn M, Pihlajaniemi T, Hofmann K, Bucher P. The frizzled motif: in how many different protein families does it occur? Trends Biochem Sci 1998;23:415-7.
5. Anilkumar N, Annis DS, Mosher DF, Adams JC. Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci 2002;115:2357-66.
6. Kuo CJ, LaMontagne KR Jr, Garcia-Cardena G, Ackley BD, Kalman D, Park S, Christofferson R, Kamihara J, Ding YH, Lo KM, Gillies S, Folkman J, et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NCl/endostatin domain. J Cell Biol 2001;152:1233-46.
7. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombarde C, Pihlajaniemi T, Alitalo K, Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-9.
8. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 2002;16:706-8.
9. Wickstrom SA, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo K, Keski-Oja J. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res 2001;61:6511-6.
10. Wilson RF, Morse MA, Pei P, Renner RJ, Schuller DE, Robertson FM, Mallery SR. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res 2003;23:1289-95.
11. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
13. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6.
14. Mallery SR, Pei P, Kang J, Ness GM, Ortiz R, Touhalisky JE, Schwendeman SP. Controlled-release of doxorubicin from poly(lactide-co-glycolide) microspheres significantly enhances cytotoxicity against cultured AIDS-related Kaposi's sarcoma cells. Anticancer Res 2000;20:2817-25.
15. Ollins GJ, Nikitakis N, Norris K, Herbert C, Siavash H, Sauk JJ. The production of the endostatin precursor collagen XVIII in head and neck carcinomas is modulated by CBP2/Hsp47. Anticancer Res 2002;22:1977-82.
16. Stewart J, Siavash H, Hebert C, Norris K, Nikitakis NG, Sauk JJ. Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells. Oral Oncol 2003;39:862-9.
17. Goldstein S, Russo A, Samuni A. Reactions of PTIO and carboxy-PTIO with *NO, *NO2, and O2-*. J Biol Chem 2003;278:50949-55.
18. Nyberg P, Heikkila P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, Pihlajaniemi T, Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003;278:22404-11.
19. Ye C, Feng C, Wang S, Wang KZ, Huang N, Liu X, Lin Y, Li M. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004;145:817-22.
20. Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H, Khattar P, Mishal Z, Perricaudet M, Li H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003;14:997-1008.
21. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
22. Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: beta-catenin as a potential target? Cancer Lett 2003;196:1-12.
23. Javaherian K, Park SY, Pickl WF, LaMontagne KR, Sjin RT, Gillies S, Lo KM. Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J Biol Chem 2002;277:45211-8.
24. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001;159:993-1008.
25. Deininger MH, Wybranietz WA, Graepler FT, Lauer UM, Meyermann R, Schluesener HJ. Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. FASEB J 2003;17:1267-76.
26. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-55.
27. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
28. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94.
29. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-6.
30. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004;10:33-42.
31. Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. J Pediatr Surg 2003;38:1499-505.
32. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74.
33. Abdollahi A, Hahnfeldt P, Maercher C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.